Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2021 Jun 29;9(8):502–514. doi: 10.1016/S2213-8587(21)00139-X

Table 2A:

Safety Experience of Trial Participants: Adverse Events Severity by Treatment Group

Severity (Grade) Treatment Group
Imatinib No. of subjects (%) Placebo No. of subjects (%)
0/1 13 (28.9) 9 (40.9)
2 21 (46.7) 10 (45.5)
3 7 (15.6) 2 (9.1)
4 3 (6.7) 1 (4.5)
5 1 (2.2) 0 (0.0)
Total 45 (100.0) 22 (100.0)